On 17 February 2026, Alzheimer Europe held a session of its popular online workshop series, the Alzheimer's Association Academy, together with Project Alzheimer’s Value Europe (PAVE). This was the second Academy of 2026 and focused on the topic of "Pathways to access for Alzheimer’s treatments: HTA and reimbursement".
Jean Georges, Executive Director, Alzheimer Europe, opened the session, welcoming over 50 participants from 17 countries and six companies.
Speakers at the session included:
Laura Campo (Executive Director, International Corporate Affairs, Alzheimer’s Disease, Lilly; PAVE Steering Committee) and Olivia LeSueur (Director, High Lantern Group; PAVE Secretariat), who delivered a presentation introducing PAVE and its activities and tools to advance access to new therapies
Linus Jönsson (Professor of Health Economics, Karolinska Institutet, Sweden), who shared some of the concepts and challenges around health economics in HTA evaluations for Alzheimer’s disease (AD)
Angela Bradshaw (Director for Research, Alzheimer Europe), who provided an update on HTA processes for disease-modifying therapies in Europe
David Thomas (Head of Policy and Public Affairs, Alzheimer’s Research UK), who shared some reflections on the HTA process in the United Kingdom
Following these presentations, Lydia Lanman (Senior Global Policy Leader, Hoffmann-La Roche; PAVE Steering Committee) led a panel discussion about navigating HTA realities in practice, including questions from the audience.
The Alzheimer’s Association Academy is a series of online capacity-building workshops bringing together representatives of national Alzheimer’s associations with members of the European Working Group of People with Dementia (EWGPWD) and European Dementia Carers Working Group (EDCWG), as well as representatives from pharmaceutical companies, to learn about dementia advocacy, care, policy, research and treatment.
Project Alzheimer’s Value Europe (PAVE) is a consortium of organisations created to increase collaboration and understanding between key stakeholders in the Alzheimer’s ecosystem within Europe, including regulators, bodies responsible for health technology assessment, payers, clinicians, patient advocates and industry. PAVE’s work builds on the Pathways for the Introduction of Alzheimer’s disease Treatments (PIAdT) initiative and leverages European-focused stakeholders and experts. Find out more about PAVE: https://www.paveurope.com/
During the session, a PAVE toolkit, which explains how Health Technology Assessment (HTA) works across Europe and provides guidance for patients, caregivers, and advocacy groups to participate meaningfully at each stage of the process, was presented. You can find it here:
A huge thank you to all speakers and participants at the Academy of 17 February, to co-hosts PAVE, and to our Gold and Silver sponsors, Bristol Myers Squibb, Eisai, Lilly and Roche as well as to the European Union’s Citizen’s, Equalities, Rights and Values (CERV) programme, without whom our Academy sessions would not be possible.
